BRAF and melanoma: Immunotherapy is significantly improving long-term survival in a subset ofmelanoma patients [1], and new drugs, particularlythose that target mutant BRAF found in about 50% of melanoma, have provided some hope,but resistance and relapse are typically encountered [2].